e-learning
resources
Amsterdam 2011
Sunday, 25.09.2011
Rare diffuse lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Lymphocytes populations in bloods and lungs in patients with auto-immune pulmonary alveolar proteinosis
Y. Inoue, T. Arai, J. Otsuka, C. Sugimoto, M. Hirose, A. Natsumuro, Y. Iwaki, M. Nakagawa, S. Hayashi, M. Okada (Osaka, Japan)
Source:
Annual Congress 2011 - Rare diffuse lung diseases
Session:
Rare diffuse lung diseases
Session type:
Thematic Poster Session
Number:
631
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Inoue, T. Arai, J. Otsuka, C. Sugimoto, M. Hirose, A. Natsumuro, Y. Iwaki, M. Nakagawa, S. Hayashi, M. Okada (Osaka, Japan). Lymphocytes populations in bloods and lungs in patients with auto-immune pulmonary alveolar proteinosis. Eur Respir J 2011; 38: Suppl. 55, 631
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions
Pulmonary sarcoidosis
Related content which might interest you:
Pulmonary alveolar proteinosis
Source: Respipedia Article
Year: 2017
Our cases with pulmonary alveolar proteinosis
Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs)
Year: 2018
Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis
Source: Eur Respir J 2012; 39: 777-780
Year: 2012
The benefits of whole lung lavage in pulmonary alveolar proteinosis
Source: Eur Respir J 2004; 23: 503-505
Year: 2004
Determinants of protein concentration in whole lung lavage of patients with pulmonary alveolar proteinosis
Source: Annual Congress 2009 - From genetics to clinics in diffuse parenchymal lung diseases
Year: 2009
Intercurrent intractable factors in autoimmune pulmonary alveolar proteinosis
Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease
Year: 2009
CD8+ T-cell alveolitis in familial pulmonary alveolar microlithiasis
Source: Eur Respir J 2007; 30: 165-171
Year: 2007
Lung cysts in pulmonary alveolar proteinosis.
Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs)
Year: 2018
PAS-negative pulmonary alveolar proteinosis
Source: Annual Congress 2008 - Rare clinical cases
Year: 2008
Whole lung lavage (WLL) for patients with pulmonary alveolar proteinosis
Source: Eur Respir J 2004; 24: Suppl. 48, 670s
Year: 2004
KL-6 in whole lung lavage fluid of patients with pulmonary alveolar proteinosis
Source: Annual Congress 2009 - Sarcoidosis and profiles of other diffuse parenchymal lung disease
Year: 2009
Surveillance of whole lung lavage for autoimmune pulmonary alveolar proteinosis in Japan
Source: Annual Congress 2013 –Diffuse parenchymal lung disease I
Year: 2013
Mini-whole lung lavage to treat pulmonary alveolar proteinosis (PAP)
Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Year: 2020
Pulmonary alveolar proteinosis and idiopathic pulmonary hemosiderosis
Source: International Congress 2019 – CCC Airway diseases
Year: 2019
Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis
Source: Eur Respir J 2004; 23: 526-531
Year: 2004
Neutralizing capacity of autoantibody against GM-CSF in patients with autoimmune pulmonary alveolar proteinosis
Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs)
Year: 2018
Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis
Source: Eur Respir J, 49 (5) 1700407; 10.1183/13993003.00407-2017
Year: 2017
Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis
Source: Eur Respir J, 49 (5) 1700178; 10.1183/13993003.00178-2017
Year: 2017
Airway dendritic cell phenotypes in inflammatory diseases of the human lung
Source: Eur Respir J 2007; 30: 878-886
Year: 2007
Idiopathic pulmonary alveolar proteinosis: GM CSF therapy and whole lung lavage a case report
Source: Eur Respir J 2003; 22: Suppl. 45, 44s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept